250 related articles for article (PubMed ID: 792355)
21. Amphotericin B lipid complex therapy of experimental fungal infections in mice.
Clark JM; Whitney RR; Olsen SJ; George RJ; Swerdel MR; Kunselman L; Bonner DP
Antimicrob Agents Chemother; 1991 Apr; 35(4):615-21. PubMed ID: 2069367
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis.
Sugar AM; Liu XP
Antimicrob Agents Chemother; 1996 May; 40(5):1314-6. PubMed ID: 8723494
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of nucleotide biosynthesis potentiates the antifungal activity of amphotericin B.
Banerjee D; Burkard L; Panepinto JC
PLoS One; 2014; 9(1):e87246. PubMed ID: 24498052
[TBL] [Abstract][Full Text] [Related]
24. Comparative susceptibility of four kinds of pathogenic fungi to amphotericin B and amphotericin B methyl ester.
Huston AC; Hoeprich PD
Antimicrob Agents Chemother; 1978 Jun; 13(6):905-9. PubMed ID: 354519
[TBL] [Abstract][Full Text] [Related]
25. Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles.
Brajtburg J; Elberg S; Travis SJ; Kobayashi GS
Antimicrob Agents Chemother; 1994 Feb; 38(2):294-9. PubMed ID: 8192455
[TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine.
Mitsuyama J; Nomura N; Hashimoto K; Yamada E; Nishikawa H; Kaeriyama M; Kimura A; Todo Y; Narita H
Antimicrob Agents Chemother; 2008 Apr; 52(4):1318-24. PubMed ID: 18227186
[TBL] [Abstract][Full Text] [Related]
27. Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis.
Perfect JR; Durack DT
Antimicrob Agents Chemother; 1985 Dec; 28(6):751-5. PubMed ID: 4083860
[TBL] [Abstract][Full Text] [Related]
28. Activity of phenothiazines against medically important yeasts.
Eilam Y; Polacheck I; Ben-Gigi G; Chernichovsky D
Antimicrob Agents Chemother; 1987 May; 31(5):834-6. PubMed ID: 3300543
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology.
Keele DJ; DeLallo VC; Lewis RE; Ernst EJ; Klepser ME
Diagn Microbiol Infect Dis; 2001 Nov; 41(3):121-6. PubMed ID: 11750164
[TBL] [Abstract][Full Text] [Related]
30. Letter: Amphotericin B and 5-fluorocytosine.
Medoff G; Kobayashi GS
J Infect Dis; 1975 Oct; 132(4):489-90. PubMed ID: 1102615
[No Abstract] [Full Text] [Related]
31. In vivo and in vitro antifungal activity of the polyene derivative SPA-S-753 against encapsulated form of Cryptococcus neoformans.
Strippoli V; D'Auria FD; Simonetti N; Basti D; Bruzzese T
Infection; 1997; 25(1):27-31. PubMed ID: 9039534
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
Schwarz P; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
[TBL] [Abstract][Full Text] [Related]
33. A novel injectable water-soluble amphotericin B-arabinogalactan conjugate.
Falk R; Domb AJ; Polacheck I
Antimicrob Agents Chemother; 1999 Aug; 43(8):1975-81. PubMed ID: 10428922
[TBL] [Abstract][Full Text] [Related]
34. Effect of culture media on the antifungal activity of miconazole and amphotericin B methyl ester.
Hoeprich PD; Huston AC
J Infect Dis; 1976 Oct; 134(4):336-41. PubMed ID: 789787
[TBL] [Abstract][Full Text] [Related]
35. Effects of ascorbic acid on the antifungal action of amphotericin B.
Brajtburg J; Elberg S; Kobayashi GS; Medoff G
J Antimicrob Chemother; 1989 Sep; 24(3):333-7. PubMed ID: 2681119
[TBL] [Abstract][Full Text] [Related]
36. Dectin-2-Targeted Antifungal Liposomes Exhibit Enhanced Efficacy.
Ambati S; Ellis EC; Lin J; Lin X; Lewis ZA; Meagher RB
mSphere; 2019 Oct; 4(5):. PubMed ID: 31666315
[No Abstract] [Full Text] [Related]
37. Comparative susceptibility of Candida albicans to amphotericin B and amphotericin B methyl ester.
Bannatyne RM; Cheung R
Antimicrob Agents Chemother; 1977 Oct; 12(4):449-50. PubMed ID: 335958
[TBL] [Abstract][Full Text] [Related]
38. Treatment of experimental systemic mycoses with BRL 49594A.
Najvar LK; Luther MF; Graybill JR
J Antimicrob Chemother; 1995 Dec; 36(6):1005-1011. PubMed ID: 8821599
[TBL] [Abstract][Full Text] [Related]
39. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome).
Adler-Moore JP; Chiang SM; Satorius A; Guerra D; McAndrews B; McManus EJ; Proffitt RT
J Antimicrob Chemother; 1991 Oct; 28 Suppl B():63-71. PubMed ID: 1778893
[TBL] [Abstract][Full Text] [Related]
40. In vitro antifungal activity of eugenol and vanillin against Candida albicans and Cryptococcus neoformans.
Boonchird C; Flegel TW
Can J Microbiol; 1982 Nov; 28(11):1235-41. PubMed ID: 6758923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
